Cannabis Equity UCITS ETF
Europe's first hemp & cannabis equity fund
CanSoul identifies promising listed hemp and cannabis companies worldwide and opens up access to this market for private and institutional investors.
Europe's first hemp and cannabis equity fund – global, exchange-traded, actively managed.
- WKN
- A2PX8U
- ISIN
- LI0514446843
Positioning
One fund for the entire value chain of the hemp plant.
The fund identifies promising listed hemp and cannabis companies worldwide and invests up to 100 % in hemp equities, initially predominantly in North America.
The investment processes are continuously refined in dialogue with industry experts. The sector is highly volatile; the strategy is long-term.
Value chain covered
- Cultivation
- Patents and licences
- Research
- Technology
- Extraction
- Software
- Distribution
- Product range
- Infrastructure
- CBD
- Adult use
- Pharmaceuticals
Three themes
Where the hemp plant moves markets
-
Theme 01
Recreational cannabis
The global wave of legalisation continues unabated
Learn more -
Theme 02
CBD & medical cannabis
On the rise worldwide and scientifically recognised. Used successfully in epilepsy and oncology, among other fields
Learn more -
Theme 03
Industrial hemp & sustainability
Hemp will be one of the decisive bio-based raw materials of the future, offering sustainable answers to today's global crises
Learn more
The fund in figures
Key facts
Source: IFM Independent Fund Management AG; portfolio according to the CanInsight profile.
-
28
companies in the portfolio from the USA and Canada (as of 28 Aug 2026)
-
12
industry segments of the hemp economy considered
-
11.7m €
fund assets (as of 28 Sep 2026)
-
4.00€
unit price of share class EUR-S (as of 28 Sep 2026)
The sole basis for purchasing units are the sales documents valid at the time. Past performance is not a reliable indicator of future results.
Value chain
From cultivation to the stock exchange
CanSoul looks at the hemp and cannabis industry along its entire value chain – from cultivation through extraction and product to distribution and the capital market.
The portfolio includes licensed producers, multi-state and multi-country operators, REITs, equipment suppliers, pharmaceutical, extraction, CBD, food & drink and software companies.
- 01 Cultivation
- 02 Extraction
- 03 Product
- 04 Distribution
- 05 Stock exchange
-
Stage 01 of 05
Cultivation
Licensed producers and multi-state operators grow the plant – in greenhouses, outdoors and indoors. Equipment suppliers and REITs provide technology and land.
-
Stage 02 of 05
Extraction
Flowers and biomass are turned into extracts, isolates and active ingredients – the basis for CBD products, pharmaceuticals and cannabis 2.0.
-
Stage 03 of 05
Product
Flowers, oils, edibles, beverages, cosmetics, superfood and building materials: the product range spans from adult use to industry.
-
Stage 04 of 05
Distribution
Licensed sale to adults in legalised jurisdictions, pharmacies, specialist retail and online – supported by software and infrastructure.
-
Stage 05 of 05
Stock exchange
CanSoul bundles selected listed companies from this chain in a UCITS fund, giving private and institutional investors access to the market.
Market overview
A market being reshaped by regulation
- Since 28 April 2026 the US Drug Enforcement Administration lists medical cannabis from state-licensed programmes and FDA-approved cannabis products in Schedule III. Licensed medical operators are no longer subject to tax rule 280E. A decision on full rescheduling follows the hearing held in summer 2026.
- 24 US states and Washington, D.C. allow adult use of cannabis; 41 states allow medical use.
- Germany legalised possession and home cultivation for adults on 1 April 2024. Imports of medical cannabis rose to 201 tonnes in 2025, almost three times the previous year.
- In April 2026 Canadian producer Organigram acquired Berlin-based Sanity Group for up to 250 million euros, the largest acquisition in the German market to date.
-
$29.1 bn
legal cannabis sales in the USA in 2025 (Whitney Economics)
-
C$5.6 bn
Canadian cannabis retail sales in 2025 (Statistics Canada)
-
201 t
medical cannabis imported into Germany in 2025 (BfArM)
-
$14.5 bn
market capitalisation of listed cannabis companies, September 2026 (companiesmarketcap.com)
Uses of the plant
- Superfood
- Building materials
- Pharmaceuticals
- Natural fibres
- Lifestyle
Trailer
CanSoul on film
The trailer for Europe's first hemp & cannabis equity fund.
Partners